AIP
PTCT icon

Arrowpoint Investment Partners’s PTC Therapeutics PTCT Stock Holding History

Arrowpoint Investment Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.01M Sell
36,873
-2,828
-7% -$204K 0.66% 29
2026
Q1 		$2.7M Buy
39,701
+30,463
+330% +$2.16M 2.4% 12
2025
Q4 		$702K Buy
9,238
+5,947
+181% +$432K 0.1% 59
2025
Q3 		$202K Buy
+3,291
New +$171K 0.2% 66

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Arrowpoint Investment Partners's PTCT Position: Q2 2026 in Review

Arrowpoint Investment Partners reduced its PTC Therapeutics (PTCT) stake by 7.1% in Q2 2026, selling an estimated $204K and leaving 36,873 shares worth $3.01M. The position accounts for 0.66% of the portfolio, ranked #29.

Arrowpoint Investment Partners first reported a position in PTCT in Q3 2025 and has held it in 4 quarters since. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Arrowpoint Investment Partners held 36,873 shares of PTC Therapeutics worth $3.01M as of Q2 2026.
  • Arrowpoint Investment Partners sold 2,828 PTC Therapeutics shares in Q2 2026, an estimated $204K.
  • PTC Therapeutics made up 0.66% of Arrowpoint Investment Partners's portfolio in Q2 2026, its #29 holding.
  • Arrowpoint Investment Partners first reported a position in PTC Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Arrowpoint Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.